Biodexa Pharmaceuticals Plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BDRX | GNPX | PCSA | XBIO | SLXN | VAL.L | |
|---|---|---|---|---|---|---|
| Market cap | 1.41M | 1.75M | 5.41M | 4.71M | 2.34M | 2.11M |
| P/E (TTM) | 0.0 | — | — | — | — | — |
| Forward P/E | — | -1.0 | -0.5 | -3.0 | -0.2 | 0.0 |
| Price/book | 0.0 | 0.1 | -17.0 | 0.8 | 19.2 | 0.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −98.73% | −98.21% | −75.51% | −26.10% | −99.49% | −31.91% |
| Today | −4.61% | −7.36% | −0.26% | −3.37% | +0.59% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All BDRX news ›Biodexa Pharmaceuticals Announces Reverse ADS Ratio Change Effective Late October 2026
Biodexa Pharmaceuticals ( (BDRX) ) has provided an update. Spark’s Take on BDRX Stock According to Spark, TipRanks’ AI Analyst, BDRX is a Neutral. Overall score is held down mainly by weak financial performance (no revenue, ongoing losses,…
Beldex Announces Two-Year Strategic Suspension of Allocated BDX Releases
Beldex is introducing a two-year strategic suspension of scheduled releases from its remaining allocated BDX holdings, marking a shift from quarterly token releases toward a longer-term approach to ecosystem development and token…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- beldexofficial.medium.com1
- theglobeandmail.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.